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The long arm of chromosome 8 is one of the most common regions of amplification in cancers of several organs, especially
carcinomas of the breast and prostate. TRPS1, MYC and EIF3S3 genes are located in one of the minimal regions of amplification,
8q23–q24, and have been suggested to be the target genes of the amplification. Here, our goal was to study copy number and
expression of the three genes in order to investigate the significance of the genes in breast and prostate cancer. By using fluorescence
in situ hybridisation (FISH), we first found that TRPS1 and EIF3S3 were amplified together in about one-third of hormone-refractory
prostate carcinomas. Next, we analysed the mRNA expression of the three genes by real-time quantitative RT–PCR and the gene
copy number by FISH in six breast and five prostate cancer cell lines. Breast cancer cell line, SK-Br-3, which contained the highest copy
number of all three genes, showed overexpression of only EIF3S3. Finally, the expression levels of TRPS1, EIF3S3 and MYC were
measured in freshly frozen clinical samples of benign prostate hyperplasia (BPH), as well as untreated and hormone-refractory
prostate carcinoma. The TRPS1 and MYC expression levels were similar in all prostate tumour groups, whereas EIF3S3 expression
was higher (P¼0.029) in prostate carcinomas compared to BPH. The data suggest that the expression of EIF3S3 is increased in
prostate cancer, and that one of the mechanisms underlying the overexpression is the amplification of the gene.
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Molecular cytogenetic analyses, especially comparative genomic
hybridisation (CGH), have indicated that gain of the long arm of
chromosome 8 (8q) is one of the most common chromosomal
aberrations in many human malignancies, including breast and
prostate carcinomas (Forozan et al, 1997). For example, about
70–90% of metastatic and/or hormone-refractory prostate carci-
nomas as well as about 50% of untreated breast cancers contain
gain of 8q by CGH (Visakorpi et al, 1995; Cher et al, 1996;
Tirkkonen et al. 1998; Nupponen et al, 1999). The gain of 8q has
also been found to be associated with an aggressive phenotype and
poor prognosis in these malignancies (Isola et al, 1995; Alers et al,
2000). Two minimal regions of amplification, 8q21 and 8q23–q24,
have been identified in prostate cancer by CGH analyses (Cher
et al, 1996; Nupponen et al, 1998). Several putative target genes,
such as MYC, PSCA, EIF3S3 and TRPS1, have been proposed for
the amplification of 8q23–24 (Jenkins et al, 1997; Reiter et al, 1998;
Nupponen et al, 1999; Chang et al, 2000; Rummukainen et al.
2001). However, the significance of each of these genes in
tumorigenesis is unclear.
MYC, located at 8q24.1, is a well characterised oncogene, which
is involved in early embryogenesis, control of cell growth, cell
differentiation and apoptosis (Giaccia and Denko, 2000). Its
overexpression or amplification has been found in several cancer
types, including breast and prostate cancer (Jenkins et al, 1997;
Nupponen et al, 1998; Rummukainen et al, 2001).
We have recently identified two putative target genes for 8q
amplification, EIF3S3 and TRPS1 (alias GC79) both located at 8q23
(Nupponen et al, 1999; Chang et al, 2000). Using suppression
subtraction hybridisation (SSH), EIF3S3 was found to be over-
expressed in breast cancer cell line SK-Br-3, which contains a high-
level amplification at 8q23–q24 by CGH (Nupponen et al, 1999).
Subsequently, it was found that the gene is amplified in about 30–
50% of hormone-refractory, but only in 10–20% of untreated
prostate carcinomas. The amplification of the gene has been found
to be associated with high Gleason score (Sarama ¨ki et al, 2001). In
addition, about 20% of untreated breast cancers contain amplifica-
tion of EIF3S3 gene (Nupponen et al, 1999). The EIF3S3 gene
encodes for a p40 subunit of eukaryotic translation initiation
factor 3 (eIF3). The eIF3 complex plays a central role in the
translation initiation pathway by binding to 40S ribosomal
subunits in the absence of other translational components, and it
helps to maintain the 40S and 60S subunits in a dissociated state
(Asano et al, 1997). The function of the p40 subunit itself is,
however, not known. It has been suggested that also some other
translation initiation factors might be involved in the development
of malignancies. For example, the overexpression of EIF4E as well
as EIF4G1 has been shown to transform normal cells (De Benedetti
and Rhoads, 1990; Fukuchi-Shimogori et al, 1997) and increased
expression of EIF4E has been found in breast cancer cell lines
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y(Anthony et al, 1996). In addition, a recent cDNA microarray study
suggested that upregulation of several genes of translation
apparatus is generally involved in metastasis of cancer (Ramaswa-
my et al, 2003).
TRPS1 was recently found to be more expressed in androgen-
dependent than androgen-independent LNCaP prostate cancer cell
lines by differential display analysis (Chang et al, 2000). TRPS1
encodes a zinc-finger GATA-type nuclear protein, which has been
implicated in apoptosis. Castration leads to increased expression
of TRPS1 in rat ventral prostate (Chang et al, 2000, 2002). Germ-
line mutations in the TRPS1 gene, on the other hand, cause tricho-
rhino-phalangeal syndrome (TRPS) types I and III (Momeni et al,
2000, Lu ¨decke et al, 2001). In addition, it was reported that
xenopus TRPS1 acts as a repressor of the xenopus GATA4
transcription factor (Malik et al, 2001). This suggests that human
TRPS1 could be involved in gene regulation of the family of human
GATA transcription factors.
In order to evaluate the significance of EIF3S3, MYC, and TRPS1
in breast and prostate cancer, we have analysed the expression and
copy number of the three genes in cell lines and tumours using
quantitative real-time RT–PCR and fluorescence in situ hybridisa-
tion (FISH).
MATERIALS AND METHODS
Cell lines and tumour samples
Five prostate cancer cell lines (PC-3, LNCaP, DU145, 22rv1 and
NCI-H660) and six breast cancer cell lines (SK-Br-3, ZR75-1, MCF-
7, MDA436, EFM19 and T47D) were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA) and cultured
under the recommended conditions. Freshly frozen specimens
from nine benign prostate hyperplasias (BPH), 35 untreated
primary (from 34 prostatectomies and one transurethral resection
of the prostate) and 12 locally recurrent hormone-refractory (from
transurethral resections of the prostate) prostate carcinomas were
obtained from the Tampere University Hospital. The specimens
were histologically examined for the presence of more than 60% of
cancerous or hyperplastic tissue using haematoxylin and eosin-
stained slides. The BPH samples were obtained from prostatect-
omy specimens from cancer patients. However, the specimens
were histologically verified not to contain any cancer cells. The
TNM distribution of the untreated cases was pT1N0M0, 2;
pT2N0M0, 12; pT2N1M0, 2; pT3N0M0, 13; T4NXM0, 1; TXN0M0,
1; TXNXMX, 4. Of the untreated primary carcinomas, 11 were
grade I, 16 grade II and seven grade III. Histological grade
information was not available for one case. In the hormone-
refractory cases, time from the beginning of the therapy to TURP
varied from 15 to 60 months. In addition, a tissue microarray
(TMA) containing 48 locally recurrent (TURP samples) hormone-
refractory formalin-fixed paraffin-embedded prostate carcinomas
from the Tampere University Hospital, was constructed according
to previously published guidelines (Kononen et al, 1998). The use
of clinical tumour material has been approved by the Ethical
Committee of the Tampere University Hospital.
RT–PCR
One to three 20mm frozen sections were cut using a cryotome. The
total RNAs were isolated from the sections using Qiagen RNeasy
MiniKit (Qiagen Inc., Valencia, CA, USA), and used for the first-
strand cDNA synthesis with Superscriptt II reverse transcriptase
and oligo d(T)12–18 primer according to the manufacturer’s
protocol (Life Technologies, Gaithersburg, MD, USA). For prepar-
ing the standard curve, 5mg of total RNA from the prostate cancer
cell line LNCaP (ATCC, Manassas, VA, USA) was reverse
transcribed as described above. After the first-strand cDNA
synthesis, serial dilutions (1:5) were made to correspond to cDNA
transcribed from 500, 100, 20, 4, 0.8 and 0.16ng of total RNA.
Primers for the TRPS1, EIF3S3 and MYC genes were designed
with the Primer3 program (available at http://www-genome.wi.-
mit.edu/cgi-bin/primer3.www.cgi). To avoid amplification of any
genomic DNA, the forward and reverse primers for each gene were
chosen from different exons. The sizes of the PCR products
were designed to be under 400bp to optimise the RT–PCR
measurements. The primer and probe sequences for the genes are
given in Table 1.
The PCR reactions were performed with a LightCyclert
instrument using the LightCycler – FastStart DNA Master
Hybridization Probes Kit (EIF3S3 and MYC) or FastStart DNA
Master SYBR Green I Kit (TRPS1) (Roche Diagnostics, Mannheim,
Germany). Thermocycling for each reaction was carried out in a
final volume of 20ml containing 2ml of cDNA sample (or standard),
4m M MgCl2, 0.5mM of each primer, 0.2mM of fluorescein and 0.4mM
LC Red640 labelled probes (or SYBR Green I stain in TRPS1 assay),
as well as 1  ready-to-use reaction mix including Taq DNA
polymerase, reaction buffer and dNTP mix. After 10min of initial
denaturation at þ951C, the cycling conditions of 50 cycles
consisted of denaturation at þ951C for 1s (EIF3S3 and MYC) or
10s (TRPS1), annealing at þ581C for 10s (EIF3S3 and MYC) or at
þ601C for 7s (TRPS1) and elongation at þ721C for 10s (EIF3S3)
or 13s (MYC) or 7s (TRPS1). After the PCR reaction and
fluorescence measurements, fit point method together with back-
ground adjustment was used to determine the cycle in which the
log-linear signal was distinguished from the background, and that
cycle number was used as the crossing-point value. The software
produced the standard curve by measuring the crossing point
of each standard and plotting them against the logarithmic
values of concentrations (Figure 1). The expression levels of
TRPS1, EIF3S3 and MYC were normalised by the expression level
of the housekeeping gene TATA binding protein (TBP),
measured as previously described (Linja et al, 2001). The relative
expression was illustrated by dividing the EIF3S3, TRPS1 and MYC
values with the TBP value, and multiplying by 10. TBP was chosen
for the reference gene, because there are no known retro-
Table 1 Primer and probe sequences used in the real-time RT–PCR
Gene Primer sequences (50–30) Hybridization probe sequences (50–30)*
EIF3S3 GCC CAG GCT CTT CAA GAA TAC GCTGAATCTCCCGAGCCGCCTTT-Fluorescein
ATA GCC AAA ATC GGC AAT GA Red640-CCTTTGCCTTTCCCTGCTGCGC
C-MYC CCT ACC CTC TCA ACG ACA GC GCCTCCCTCCACTCGGAAGGACT-Fluorescein
CGC CTC TTG ACA TTC TCC TC Red640-TCCTGCTGCCAAGAGGGTCAAGTT
TRPS1 GTA TCC TGC ATC GGG AGA AA
AGC TTC TGG TAG AGG CCA CA
*purchased from Tib Mol Biol, Berlin, Germany.
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ypseudogenes for it and its expression is lower than that of many
commonly used abundantly expressed reference genes (Bieche
et al, 1999). After the PCR, every sample was also run in 1.2%
agarose gel electrophoresis to ensure that the right size product
was amplified in the reaction. Melting curve analysis was also used
to evaluate the quality of the PCR reaction for TRPS1.
Fluorescence in situ hybridisation
Locus-specific PAC probes for human TRPS1 (Chang et al, 2000),
EIF3S3 (Nupponen et al, 1999) and MYC (Nupponen et al, 1998)
were labelled with digoxigenin-dUTP (Roche Diagnostics), and a
pericentromeric probe for chromosome 8 (pJM128) with FITC-
dUTP (NEN, Boston, MA, USA), by nick translation. The
metaphase preparations from the cancer cell lines were prepared
using standard techniques. The dual-colour hybridisation was
performed essentially as described previously (Hyytinen et al,
1994). Briefly, the slides were denatured in a 70% formamide/
2 SSC solution (pH 7.0) at 701C for 3min and dehydrated in an
ascending ethanol series. Hybridisation was performed over two
nights at 371C. After stringent washes, the slides were stained with
antidigoxigenin-rhodamine (Roche Diagnostics) and counter-
stained with an antifade solution (Vectashied, Vector Laboratories,
Burlingame, CA, USA) containing 4,6-diamidino-2-phenylindole
(DAPI). The formalin-fixed paraffin-embedded TMAs were pre-
treated and hybridised as described previously (Sarama ¨ki et al,
2001). The FISH signals were scored from nonoverlapping
epithelial cells using Olympus BX50 epifluorescence microscope
(Tokyo, Japan). Tumours with a tight cluster of signals or at least
two-fold higher copy number of the locus-specific probe signals vs
centromeric signals or X5 copies of locus specific probe signals
were considered to contain a high-level amplification of either
gene. Tumours with three to four copies of the gene signals were
considered to have a gain of the gene.
Statistical analyses
The associations of the gene copy numbers, tumour types,
histological grades and clinical stages with expression levels were
calculated with nonparametric Kruskal–Wallis and Mann–Whit-
ney U-tests. Outliers were detected by using extreme studentised
deviate method (ESD).
RESULTS
TRPS1, EIF3S3 and MYC gene amplification
Tissue microarrays and FISH were first used to study gene copy
number of EIF3S3 and TRPS1 in hormone-refractory prostate
carcinomas. High-level amplification (X5 copies) of EIF3S3 and
TRPS1 was found in 11out of 40 (28%) and 10 out of 36 (28%) of
the cases, respectively. The gain (three to four copies) of EIF3S3
and TRPS1 was found in 19 out of 40 (48%) and 18 out of 36 (50%)
of the cases, respectively. In the cases of high-level amplification,
the genes were always coamplified. The coamplification was also
verified by hybridizing differentially-labelled gene specific probes
(biotin labelled EIF3S3 probe and AlexaFluor 594 labelled TRPS1
probe) simultaneously to the TMA.
Next, breast and prostate cancer cell lines were analysed for
copy numbers of the EIF3S3, MYC and TRPS1 genes. Of the cell
lines, the highest copy number of all the genes was found in the
breast cancer cell line SK-Br-3, which showed 47 copies of TRPS1
and 21 copies of EIF3S3 and MYC and only one copy of
chromosome 8 centromere (Figures 2 and 3). In addition, a
high-level amplification (locus/centromere ratio X2) of all three
genes was found in MDA436 and PC-3 cancer cell lines. EIF3S3 and
MYC were highly amplified also in EFM19 (Figure 3).
Expression of TRPS1, EIF3S3 and MYC
The standard curves in the real-time quantitative RT–PCR assay
showed wide dynamic range and the linear relationship between
cycle number and fluorescent threshold was strong (r
2B1). In
addition to TBP, the expression of b-actin was measured and used
alternatively for normalisation of most of the samples (data not
shown). The results were similar with both control genes. Due to
the potential problems with the b-actin retropseudogenes, TBP was
chosen for normalisation of the whole material.
Figure 3 illustrates the relative expression of TRPS1, EIF3S3 and
MYC in breast and prostate cancer cell lines. In the breast cancer
cell line SK-Br-3, which contains the highest copy number of all the
three genes investigated, EIF3S3 was the only gene that showed
remarkably high-level (three-to 10-fold compared to the other cell
lines) overexpression. The relative expression of TRPS1 was
highest in ZR75-1, which contains a loss of the gene compared
to centromere copy number. Interestingly, in most breast cancer
cell lines, the expression of TRPS1 was high compared to the
expression levels of EIF3S3 and MYC. The high expression level of
TRPS1 in the breast cancer cell lines has also been observed by
Northern and Western blot analyses (Chang et al, unpublished).
Figure 4 illustrates the relative expression of TRPS1, EIF3S3 and
MYC in BPH (n¼9), untreated primary (n¼30 for TRPS1, n¼35
for EIF3S3 and MYC) and locally recurrent hormone-refractory
(n¼12 for TRPS1, n¼11 for EIF3S3 and MYC) prostate
carcinomas. The expression of EIF3S3 was, on average, three-fold
higher (P¼0.029) in carcinomas than in BPH. There was no
difference in the level of expression of EIF3S3 in hormone-
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Figure 1 Standard curve of the MYC expression measurement by real-
time RT–PCR. (A) Serially diluted standard corresponding to cDNA
transcribed from 500, 100, 20, 4 and 0.8ng of total RNA. Cycle number is
blotted against fluorescent signal obtained in every cycle at the end of the
annealing step. (B) Standard curve blotting cycle number at the crossing-
point values of each standard against the logarithmic value of concentration
of the standards.
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were expressed in equal levels in BPH, untreated and hormone-
refractory tumours. There were no significant associations between
histological grade or clinical stage (T3–T4 and/or Nþ and/or
Mþ vs T1-2N0M0) and the expression of any of the three genes in
the untreated tumours.
DISCUSSION
Several oncogenes are activated by overexpression of the gene and
one mechanism of the overexpression is amplification of the gene
(Brodeur and Hogarty, 1998). Gain or amplification of chromo-
some 8q is one of the most common chromosomal alterations in
breast and prostate cancer (Forozan et al, 1997). However, the
target gene of the amplification is still unknown. The genes studied
here, EIF3S3, TRPS1 and MYC, have been suggested to be putative
target genes in 8q23–q24 (Jenkins et al, 1997; Nupponen et al,
1999; Chang et al, 2000). In order to evaluate the significance of
these genes in breast and prostate cancer, we analysed both the
gene copy numbers as well as the expressions of the three genes.
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Figure 2 (A) Dual colour FISH with PAC probes for EIF3S3 (green) and
TRPS1 (red) in metaphase preparation of breast cancer cell line SK-Br-3.
Multiple copies of both genes are seen in marker chromosomes. (B) Copy
numbers of TRPS1, EIF3S3, MYC and anonymous sequence tag sites (STSs)
in SK-Br-3 breast cancer cell line by FISH. The copy numbers of the STSs
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Figure 3 Relative expression and gene copy number of (A) EIF3S3,
(B) MYC and (C) TRPS1 in prostate and breast cancer cell lines by
real-time quantitative RT–PCR and FISH. The relative expression of the
genes was calculated by dividing the expression value of the gene of
interest with the expression value of housekeeping gene TBP. The relative
gene copy number was calculated by dividing the signal copy number of
the gene of interest with the signal copy number of chromosome 8
centromere. Of the cell lines, SK-Br-3 showed clearly the highest
copy number of all genes. However, only EIF3S3 was overexpressed in
the cell line.
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coamplified in about one-third of the locally recurrent hormone-
refractory prostate carcinomas (Sarama ¨ki et al, 2001). Now, it was
found that also EIF3S3 and TRPS1 are coamplified in about 30% of
the hormone-refractory prostate tumours. The finding that all
three genes are commonly coamplified in the hormone-refractory
tumours indicates that the size of the amplicon is large. The TRPS1
and EIF3S3 genes are located about 12 and 11Mb centromeric
from MYC, respectively. The large size and the relatively low copy
number of the amplicon have previously been implicated also by
CGH and FISH studies (Visakorpi et al, 1995; Cher et al, 1996;
Nupponen et al, 1998, 2000).
The majority of cancer cell lines have been established from
metastatic lesions of cancer. They typically contain more
chromosomal alterations than primary tumours, and the aberra-
tions are more confined. For example, amplicons are often smaller
and the copy numbers higher making the cell lines more
informative than the primary tumours for mapping the amplicons
(Kallioniemi et al, 1994). Of the breast and prostate cancer cell
lines, however, only SK-Br-3 shows a high-level amplification of
two (8q21 and 8q23–24) independent subarm regions by CGH
(Kallioniemi et al, 1994; Nupponen et al, 1999). Of the three genes
analysed here, TRPS1 showed the highest copy number, about
twice as high as for either EIF3S3 or MYC in SK-Br-3. Together
with our previous mapping data (Nupponen et al, 2000), the
results indicate that SK-Br-3 contains high copy numbers of all the
three genes with low copy numbers of the flanking regions
(Figure 1B). Thus, the amplicon from TRPS1 to MYC, covering a
chromosomal region of about 12Mb, contains, at least, three
independent subamplicons in SK-Br-3.
We used real-time quantitative RT–PCR approach to measure
the expression of TRPS1, EIF3S3 and MYC. In real-time PCR, the
quantification of the template is based on detection of the cycle in
which the reaction enters the exponential phase, instead of
measuring the amount of end product. Thus, none of the reagents
is rate limiting in the reaction at the time of measurement of the
fluorescence. Several studies have already shown that real-time
RT–PCR is a highly quantitative and reliable method (Bieche et al,
1999; Linja et al, 2001; Savinainen et al, 2002). It is also especially
useful in analysis of small tumour samples.
We first analysed the expression of EIF3S3, MYC and TRPS1 in
the cell lines. In SK-Br-3, which showed the highest copy number
of the genes, the expression of only EIF3S3 was remarkably high.
The high-level expression of EIF3S3, shown here by quantitative
RT–PCR, confirms our earlier Northern blot data (Nupponen et al,
1999). Surprisingly, the expression of TRPS1, whose copy number
was highest of the three genes in SK-Br-3, was lower in SK-Br-3
compared to ZR75-1. The expression of TRPS1 was the highest in
ZR75-1, which actually contains a relative loss of the gene. The
expression of MYC varied among the cell lines. SK-Br-3 containing
the highest copy number of the gene did not show clearly increased
expression compared to the other cell lines. The data suggest that
of the three genes, EIF3S3 is the most likely target gene of
amplification in SK-Br-3.
In the clinical prostate cancer specimens, the level of EIF3S3
expression was significantly (P¼0.029) higher in prostate cancer
than in BPH. The data are consistent with our previous analyses by
semiquantitative mRNA in situ hybridisation, which suggested that
EIF3S3 is expressed more in hormone-refractory prostate carci-
nomas than in BPH (Nupponen et al, 1999). Here, it was found that
the expression of EIF3S3 is increased also in untreated prostate
cancers. Somewhat surprising, the expression of EIF3S3 was not
higher in the hormone-refractory compared to the untreated
tumours, despite the fact that hormone-refractory tumours, in
general, contain higher frequency of 8q gain (Visakorpi et al,
1995). The data suggest that EIF3S3 is commonly overexpressed in
prostate cancer, and also other mechanisms than gene amplifica-
tion may lead to the overexpression of the gene. There were no
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Figure 4 Box and whisker plots displaying the relative expression of (A)
EIF3S3, (B) MYC and (C) TRPS1 in prostate tumour samples analysed by
real-time quantitative RT–PCR. The boxes indicate the area of 50% of
samples, the horizontal line in the boxes indicates median value. The
whiskers display the range. Stars depict the outlier values as estimated by
extreme studentised deviate method. The expression of EIF3S3 was
significantly (P¼0.029) higher in carcinomas than in BPH. There were no
significant differences in the expression levels of TRPS1 and MYC between
the tumour groups.
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ysignificant differences between the expression of either MYC or
TRPS1 in BPH, untreated and hormone-refractory carcinomas,
suggesting that alterations in the expression of these two genes are
not generally involved in the progression of prostate cancer.
Inconclusion,theresultsindicatethatoverexpressionofMYCand
TRPS1arerareinprostatecancerinvivo.Incontrast,theexpression
of EIF3S3 is increased in prostate cancer. One mechanism for the
overexpression of EIF3S3 seems to be amplification of the gene as
demonstrated by the cell line SK-Br-3. Analyses of the expression
levels of EIF3S3 in large clinical materials are now warranted.
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